目的:探讨上皮细胞转化序列2(ECT2)在浸润性乳腺癌中的表达及其预后意义。方法:回顾性分析2018年1月至2021年6月联勤保障部队第九〇九医院收治的165例浸润性乳腺癌患者手术治疗的临床资料,并收集患者的肿瘤组织和对应癌旁正常组织。对...目的:探讨上皮细胞转化序列2(ECT2)在浸润性乳腺癌中的表达及其预后意义。方法:回顾性分析2018年1月至2021年6月联勤保障部队第九〇九医院收治的165例浸润性乳腺癌患者手术治疗的临床资料,并收集患者的肿瘤组织和对应癌旁正常组织。对乳腺癌肿瘤组织和癌旁正常组织进行ECT2免疫组织化学染色。分析不同组织中ECT2蛋白表达情况与病理和临床资料关系。使用多因素Logistic回归分析影响ECT2蛋白高表达的因素。利用Kmplot在线生存分析公共数据库,使用Kaplan-Meier法比较ECT2高表达与ECT2低表达乳腺癌患者的生存时间差异。结果:乳腺癌组织中的ECT2表达比例高于癌旁正常组织[57.58%(95/165)比12.73%(21/165)],差异有统计学意义( χ^(2)= 76.19, P<0.01)。ECT2高表达组患者的病理组织学分级更差[G 1级30.53%(29/95)比57.14%(40/70),G 2级40.00%(38/95)比28.57%(20/70),G 3级29.47%(28/95)比14.20%(10/40)]、存在淋巴结转移更高[71.58%(68/95)比7.14%(5/70)]、TNM分期更差[Ⅰ期15.79%(15/95)比34.29%(24/70),Ⅱ期27.37%(26/95)比27.14%(19/70),Ⅲ期41.05%(39/95)比28.57%(20/70),Ⅳ期15.79%(15/95)比10.00%(7/70)]、绝经比例更高[60.00%(57/95)比44.29%(31/70)]和Ki-67增殖指数更高[74.74%(71/95)比58.57%(41/70)]( P均<0.05)。淋巴结转移( OR = 2.764, P = 0.038)、病理组织学分级为G 3级( OR = 1.942, P = 0.010)、TNM分期为Ⅳ期( OR = 2.586, P<0.001)、Ki-67增殖指数≥14%( OR = 1.376, P = 0.006)是乳腺癌患者肿瘤组织ECT2蛋白高表达的影响因素。ECT2高表达乳腺癌患者生存期更差,差异有统计学意义( P<0.05)。 结论:浸润性乳腺癌肿瘤组织中ECT2蛋白表达增加。ECT2高表达的乳腺癌患者预后更差,ECT2可能是乳腺癌治疗的潜在分子靶点,值得进一步研究。展开更多
BACKGROUND: Pancreatic cancer is closely related to epigenetic abnormality. The epithelial cell transforming sequence 2 gene (ECT2) plays a critical role in Rho activation during cytokinesis, and thus may play a role ...BACKGROUND: Pancreatic cancer is closely related to epigenetic abnormality. The epithelial cell transforming sequence 2 gene (ECT2) plays a critical role in Rho activation during cytokinesis, and thus may play a role in the pathogenesis of pancreatic cancer. In this study, we investigated the relationships between aberrant expression and epigenetic changes of the ECT2 gene in pancreatic cancer. METHODS: Four cell lines (PANC-1, Colo357, T3M-4 and PancTu I) and pancreatic ductal adenocarcinoma (PDAC) tissues were used for mRNA detection. After restriction isoschizomer endonucleases (Msp I/Hpa II) were used to digest the DNA sequence (5'-CCGG-3'), PCR was made to amplify the product. And RT-PCR was applied to determine the expression of the gene. RESULTS: The mRNA expression of the ECT2 gene was higher in pancreatic tumor tissue than in normal tissue. The gene was also expressed in the 4 PDAC cell lines. The methylation states of the upstream regions of the ECT2 gene were almost identical in normal, tumor pancreatic tissues, and the 4 PDAC cell lines. Some of the 5'-CCGG-3' areas in the upstream region of ECT2 were methylated, while others were unmethylated. CONCLUSIONS: The oncogene ECT2 is overexpressed in pancreatic tumor tissues as verified by RT-PCR detection. The methylation status of DNA in promoter areas is involved in the gene expression, along with other factors, in pancreatic cancer.展开更多
文摘目的:探讨上皮细胞转化序列2(ECT2)在浸润性乳腺癌中的表达及其预后意义。方法:回顾性分析2018年1月至2021年6月联勤保障部队第九〇九医院收治的165例浸润性乳腺癌患者手术治疗的临床资料,并收集患者的肿瘤组织和对应癌旁正常组织。对乳腺癌肿瘤组织和癌旁正常组织进行ECT2免疫组织化学染色。分析不同组织中ECT2蛋白表达情况与病理和临床资料关系。使用多因素Logistic回归分析影响ECT2蛋白高表达的因素。利用Kmplot在线生存分析公共数据库,使用Kaplan-Meier法比较ECT2高表达与ECT2低表达乳腺癌患者的生存时间差异。结果:乳腺癌组织中的ECT2表达比例高于癌旁正常组织[57.58%(95/165)比12.73%(21/165)],差异有统计学意义( χ^(2)= 76.19, P<0.01)。ECT2高表达组患者的病理组织学分级更差[G 1级30.53%(29/95)比57.14%(40/70),G 2级40.00%(38/95)比28.57%(20/70),G 3级29.47%(28/95)比14.20%(10/40)]、存在淋巴结转移更高[71.58%(68/95)比7.14%(5/70)]、TNM分期更差[Ⅰ期15.79%(15/95)比34.29%(24/70),Ⅱ期27.37%(26/95)比27.14%(19/70),Ⅲ期41.05%(39/95)比28.57%(20/70),Ⅳ期15.79%(15/95)比10.00%(7/70)]、绝经比例更高[60.00%(57/95)比44.29%(31/70)]和Ki-67增殖指数更高[74.74%(71/95)比58.57%(41/70)]( P均<0.05)。淋巴结转移( OR = 2.764, P = 0.038)、病理组织学分级为G 3级( OR = 1.942, P = 0.010)、TNM分期为Ⅳ期( OR = 2.586, P<0.001)、Ki-67增殖指数≥14%( OR = 1.376, P = 0.006)是乳腺癌患者肿瘤组织ECT2蛋白高表达的影响因素。ECT2高表达乳腺癌患者生存期更差,差异有统计学意义( P<0.05)。 结论:浸润性乳腺癌肿瘤组织中ECT2蛋白表达增加。ECT2高表达的乳腺癌患者预后更差,ECT2可能是乳腺癌治疗的潜在分子靶点,值得进一步研究。
文摘目的:检测结肠直肠癌组织及相应癌旁组织中上皮细胞转化序列2癌基因(epithelial cell transforming sequence 2 oncogene,ECT2)的m RNA表达以及蛋白质表达,并探讨其与结肠直肠癌临床病理因素的相关性及临床意义。方法:采用实时定量聚合酶链反应法检测结肠直肠癌病人的癌组织和相应癌旁组织ECT2 m RNA的表达;免疫组织化学法检测150例癌组织ECT2蛋白表达。结果:结肠直肠癌组织ECT2 m RNA表达水平明显升高(P<0.001);而ECT2蛋白表达水平与肿瘤直径(P=0.005)、CEA(P=0.006)以及TNM分期(P=0.001)密切相关。Kaplan-Meier生存曲线和Log-Rank检验提示,ECT2表达水平越高,结肠直肠癌病人预后越差(P<0.001)。多因素COX回归分析表明,ECT2在结肠直肠癌病人中可作为独立的预后分子标志物。结论:ECT2 m RNA及蛋白质在结肠直肠癌组织中均呈高表达,且ECT2表达水平越高,病人预后越差。由此可见,ECT2在结肠直肠癌的发生、发展中起重要作用,可作为反映结肠直肠癌生物学行为的有效指标。
文摘BACKGROUND: Pancreatic cancer is closely related to epigenetic abnormality. The epithelial cell transforming sequence 2 gene (ECT2) plays a critical role in Rho activation during cytokinesis, and thus may play a role in the pathogenesis of pancreatic cancer. In this study, we investigated the relationships between aberrant expression and epigenetic changes of the ECT2 gene in pancreatic cancer. METHODS: Four cell lines (PANC-1, Colo357, T3M-4 and PancTu I) and pancreatic ductal adenocarcinoma (PDAC) tissues were used for mRNA detection. After restriction isoschizomer endonucleases (Msp I/Hpa II) were used to digest the DNA sequence (5'-CCGG-3'), PCR was made to amplify the product. And RT-PCR was applied to determine the expression of the gene. RESULTS: The mRNA expression of the ECT2 gene was higher in pancreatic tumor tissue than in normal tissue. The gene was also expressed in the 4 PDAC cell lines. The methylation states of the upstream regions of the ECT2 gene were almost identical in normal, tumor pancreatic tissues, and the 4 PDAC cell lines. Some of the 5'-CCGG-3' areas in the upstream region of ECT2 were methylated, while others were unmethylated. CONCLUSIONS: The oncogene ECT2 is overexpressed in pancreatic tumor tissues as verified by RT-PCR detection. The methylation status of DNA in promoter areas is involved in the gene expression, along with other factors, in pancreatic cancer.
